Last reviewed · How we verify
TOZINAMERAN
TOZINAMERAN is a drug. It is currently FDA-approved (first approved 2020).
Tozinameran, also known as BNT-162B2, is a vaccine antigen that targets the spike glycoprotein. It is used as a component in COVID-19 vaccines, including Comirnaty, and has been studied in various clinical trials for its efficacy in conditions such as HIV, organ transplantation, lymphoma, and multiple myeloma.
At a glance
| Generic name | TOZINAMERAN |
|---|---|
| Modality | Vaccine component |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2020 |
| Annual revenue | 4367 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients (PHASE2)
- COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (PHASE4)
- Korea Comirnaty Post-marketing Surveillance
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
- Secondary Databased Post-marketing Surveillance Study of BNT162b2
- Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). (PHASE3)
- Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOZINAMERAN CI brief — competitive landscape report
- TOZINAMERAN updates RSS · CI watch RSS
Frequently asked questions about TOZINAMERAN
What is TOZINAMERAN?
When was TOZINAMERAN approved?
What development phase is TOZINAMERAN in?
What is TOZINAMERAN's annual revenue?
Related
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing